Can You Lower Your GLP-1 Dose at Goal Weight? SURMOUNT-MAINTAIN 2026 Data

Once you've reached your goal weight on tirzepatide, a natural question follows: do you really need to stay at your maximum tolerated dose forever, or can you step down to something lower and still hold the line? A Phase 3 trial called SURMOUNT-MAINTAIN, published in The Lancet on June 6, 2026, is the first randomized controlled trial to directly test that exact question — and the results give a clear, if nuanced, answer (The Lancet via European Congress on Obesity presentation, May 2026).

Here's what the trial found, what it means if you're approaching or already at your goal weight, and how the numbers compare to stopping treatment altogether.

The Trial Design

SURMOUNT-MAINTAIN enrolled 441 adults with obesity who completed 60 weeks of open-label tirzepatide at their maximum tolerated dose (10 mg or 15 mg weekly), during which they lost an average of roughly 21.8% of body weight and reached a weight plateau. From there, 378 participants who met plateau criteria were randomized 3:3:2 into three groups for an additional 52-week, double-blind maintenance period (EurekAlert / European Congress on Obesity, May 12, 2026):

• Continue tirzepatide at MTD (10 mg or 15 mg) — 140 participants
• Reduce to tirzepatide 5 mg — 144 participants
• Switch to placebo — 94 participants

The primary endpoint was percent change in body weight from baseline to week 112 — the end of the full 112-week trial.

The Results: Weight Change at Week 112

Group	Total Weight Change from Baseline	% of Prior Weight Loss Maintained
Continued MTD (10–15 mg)	−21.9%	96.5%
Reduced to 5 mg	−16.6%	67.9%
Placebo (stopped)	−9.9%	42.8%

The estimated treatment differences versus placebo were −12.0 percentage points for the MTD group and −6.6 percentage points for the 5 mg group (both p<0.0001) (American College of Cardiology summary of Lancet publication, May 18, 2026).

The "Rescue Therapy" Number That Stands Out

Perhaps the most striking finding wasn't the average weight change — it was how many patients regained enough weight to need rescue treatment. Researchers tracked how many participants in each group regained at least 50% of the weight they'd originally lost, triggering a switch to rescue tirzepatide:

• 8% of the MTD group needed rescue therapy
• 25% of the 5 mg group needed rescue therapy
• 67% of the placebo group needed rescue therapy

In other words, patients who stopped tirzepatide entirely were roughly eight times more likely to need rescue treatment than those who stayed on their maximum tolerated dose, and about 2.7 times more likely than those who simply reduced to a lower maintenance dose (American College of Cardiology). Separately reported analysis framed this same data as: patients on MTD were seven times more likely to maintain weight loss than those who stopped, while those on the reduced 5 mg dose were about four times more likely to maintain it than those who stopped entirely (EurekAlert).

Beyond the Scale: Cardiometabolic Benefits Also Tracked With Dose

The trial didn't just measure body weight. Continuing tirzepatide at either dose level — MTD or the reduced 5 mg dose — was associated with sustained improvements versus placebo in:

• BMI
• Waist circumference
• Blood glucose (glycemia)
• Blood pressure
• Lipid profile

These metabolic benefits tracked the same pattern as the weight data: bigger and more durable at the higher dose, still present but more modest at the reduced dose, and largely lost in the placebo group (American College of Cardiology).

Safety: What Changed During the Maintenance Phase

Adverse events during the initial 60-week weight-loss period included 20 participants with serious adverse events. During the 52-week maintenance period specifically, serious adverse events were rare — two in the 5 mg group and one in the placebo group. Overall, the incidence of all adverse events (not just serious ones) was higher with tirzepatide than placebo during maintenance, and mild-to-moderate gastrointestinal issues remained the most common category (American College of Cardiology).

How This Fits With the Bigger Question of Stopping GLP-1s

SURMOUNT-MAINTAIN answers a specific, narrower question than "what happens if I stop completely." It's focused on dose reduction as an alternative to full discontinuation, in a controlled trial setting. For a broader look at what newer real-world data shows about full discontinuation outcomes outside a trial setting — which paints a somewhat more encouraging picture for people who do have to stop entirely — see our companion article on what 2026's new discontinuation data actually shows.

Together, the two bodies of research point toward a similar theme: outcomes are generally better when patients have some ongoing treatment or support plan (whether that's a reduced dose, a switched medication, or structured lifestyle care) rather than stopping cold with nothing in place. If you're specifically looking for a tapering approach, see our guide on stopping GLP-1s without going cold turkey.

What This Means If You're Approaching Goal Weight

If Holding Onto Maximum Results Matters Most to You

This trial's data is fairly unambiguous: staying at your maximum tolerated dose preserved the most weight loss (96.5%) and the strongest cardiometabolic benefits.

If You're Looking for a Middle Ground

Reducing to a lower maintenance dose is a legitimate, evidence-backed option that meaningfully outperformed stopping — 67.9% maintenance versus 42.8% for placebo — even though it's not as strong as staying at full dose. This is a conversation to have directly with your prescriber, not something to self-adjust.

Tools for the Maintenance Phase

Whether you stay at full dose or step down, maintenance-phase success is closely tied to protein intake and consistent tracking. A reliable kitchen scale makes portion-based protein tracking far more consistent during this phase, and electrolyte supplements can help manage the mild GI effects that may persist even at a reduced dose.

How SURMOUNT-MAINTAIN Fits Into the Broader SURMOUNT Trial Program

SURMOUNT-MAINTAIN isn't Eli Lilly's first look at what happens after stopping tirzepatide. An earlier trial, SURMOUNT-4, tested a simpler binary question back in 2024: continue at maximum tolerated dose, or switch straight to placebo, with no reduced-dose middle option. In that trial, participants who switched to placebo experienced roughly 14% weight regain over 52 weeks, while those who continued treatment saw an additional 5.5% weight reduction — reinforcing the same general pattern SURMOUNT-MAINTAIN later confirmed with more nuance (JAMA Network summary of SURMOUNT-4).

What SURMOUNT-MAINTAIN adds that SURMOUNT-4 didn't have is the middle option — a reduced 5 mg maintenance dose — giving patients and prescribers a genuine third path between "stay at full dose forever" and "stop completely." That's a meaningfully more useful set of options for real-world treatment planning than the all-or-nothing framing of earlier research.

Who Was in the Trial

Participants were mostly female (65%), with a mean age of 47 and an average starting body weight around 114 kg (roughly 251 lbs) and BMI around 40 kg/m² — a population with substantial obesity-related comorbidity risk. This matters because the trial's findings are most directly applicable to a similar patient population; individual results can vary based on starting weight, comorbidities, and how someone responded during the initial weight-loss phase.

Practical Considerations Before Asking About a Dose Reduction

Talk Timing Matters

SURMOUNT-MAINTAIN's protocol only randomized patients who had already reached a genuine weight plateau (less than 5% body weight change over a defined window) after 60 weeks of treatment. That's a meaningful detail — the trial isn't testing what happens if you reduce your dose early, before your weight loss has actually stabilized. If you're still losing weight steadily, a dose reduction conversation is likely premature.

It's Not a One-Size-Fits-All Decision

Some patients tolerate lower doses well and maintain results; others may need to stay at a higher dose to avoid regain, particularly if they have more significant obesity-related comorbidities. Your prescriber can help weigh your specific plateau history, side-effect profile, and goals.

Rescue Therapy Is a Safety Net, Not a Failure

The trial's protocol allowed participants who regained significant weight to receive rescue tirzepatide — a reminder that if a dose reduction doesn't work for you personally, going back to a higher dose under medical supervision is a normal, built-in part of a maintenance strategy, not a sign that something went wrong.

Educational content only. Not medical advice. Any change to your GLP-1 dosing schedule should be made in consultation with your prescriber.

Frequently Asked Questions

Can I lower my tirzepatide dose once I reach my goal weight?

According to SURMOUNT-MAINTAIN trial data, reducing to a lower maintenance dose (5 mg) preserved 67.9% of prior weight loss over 52 weeks — a real middle-ground option, though not as effective as staying at your maximum tolerated dose (96.5% maintained). Any dose change should be made with your prescriber, not on your own.

What happens if I stop tirzepatide completely after reaching goal weight?

In this trial, the placebo (fully stopped) group maintained only 42.8% of their prior weight loss, and 67% needed rescue therapy after regaining at least half of what they'd lost.

What is SURMOUNT-MAINTAIN?

A Phase 3b randomized, double-blind, placebo-controlled trial published in The Lancet on June 6, 2026, testing whether tirzepatide patients who reached a weight plateau could maintain their results by continuing at maximum tolerated dose, reducing to a 5 mg dose, or stopping entirely.

Does reducing the dose still help with blood sugar and blood pressure?

Yes. The trial found sustained improvements in glycemia, blood pressure, waist circumference, and lipid profile in both the maintenance-dose group and the full-dose group compared to placebo, though benefits were generally larger at the higher dose.

How many people were in the SURMOUNT-MAINTAIN trial?

441 participants completed the initial 60-week weight-loss phase; 378 who reached a weight plateau were then randomized into the 52-week maintenance comparison.

Is SURMOUNT-MAINTAIN about semaglutide or tirzepatide?

Tirzepatide (brand names Mounjaro and Zepbound). The trial did not study semaglutide-based dose reduction.

Sources

1. EurekAlert / European Congress on Obesity — People who have lost weight using tirzepatide are seven times more likely to maintain that loss:eurekalert.org (May 12, 2026)
2. American College of Cardiology — SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight Loss:acc.org (May 18, 2026)
3. Horn DB, et al. — Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. *The Lancet*, June 6, 2026. DOI: 10.1016/S0140-6736(26)00656-2